Kodiak Sciences (KOD) Could Be 23% Undervalued On Its Retina Pipeline Story

Kodiak Sciences (KOD) has drawn fresh attention after recent price moves left the stock around $99.30, with year-to-date total return above 280% and performance over the past three months described as very large.

For context, Kodiak Sciences has moved sharply over the past year, with a 90 day share price return of 128.8% feeding into a year to date share price gain of 281.6%. The 1 year total shareholder return of 463.2% and very large 3 year total shareholder return point to momentum that has been strong rather than fading.

Scan how Kodiak Sciences fits into the wider momentum story by comparing it with a hand picked set of 19 high quality undiscovered gems that have similarly strong recent moves and fundamentals.

Kodiak Sciences now carries a market value of about US$6.2b and trades near US$99.30 after a sharp run. Investors may ask whether that price still leaves enough potential upside to justify the clinical and earnings risk buyers take on from here.

Most Popular Narrative: 18% Undervalued

Against Kodiak Sciences' last close near $99.30, the most followed narrative points to a fair value of about $121.67, which implies meaningful upside based on long duration retina assets and eventual commercialization.

The planned multi indication BLA submission for Zenkuda in Q4 2026 across wet AMD, diabetic retinopathy and retinal vein occlusion concentrates several large retinal markets into one regulatory event that could expand the treated population and increase future revenue breadth if approvals follow. The advancement of tabirafusp ted into the global Phase III ALTO trial in diabetic macular edema, with a design aimed at superiority to aflibercept and extended interval dosing, sets up a potential second high value retina product that could add incremental revenue streams and help spread Kodiak Sciences’ fixed commercial and manufacturing costs over a wider base.

See why 1 investors see Kodiak Sciences as 18% undervalued.

Result: Fair Value of $121.67 (UNDERVALUED)

Still, the Kodiak Sciences story hinges on late stage trial success and timely approvals, and any delay or setback could quickly challenge the undervaluation case.

Find out about the key risks to this Kodiak Sciences narrative.

Another View: Kodiak Sciences Looks Expensive On Book Value

The story looks very different when you swap the narrative fair value for a simple P/B check. Kodiak Sciences trades around 101.9x book value versus 1.8x for the wider US Biotechs group and about 10x for peers. That sort of gap points to meaningful valuation risk if sentiment cools.

Investors weighing the analyst upside case against this rich P/B level may want to see what the numbers imply in detail through our valuation breakdown, starting with the See what the numbers say about this price — find out in our valuation breakdown..

Next Steps

Momentum around Kodiak Sciences has been strong, so this is the moment to check the data yourself and decide how much risk feels acceptable. To weigh the potential advantages against the potential drawbacks in one place, review the 3 key rewards and 3 important warning signs.

Looking for more Kodiak Sciences style ideas?

If Kodiak Sciences has sharpened your focus on momentum and valuation, use these targeted stock lists to spot other opportunities before they move past you.

• Target dependable cash generators by scanning a list of solid balance sheet and fundamentals (25 results) that can better withstand funding shocks and earnings volatility.
• Hunt for mispriced quality using the 38 high quality undervalued stocks to see which businesses combine stronger fundamentals with prices that still look appealing.
• Lock in income potential by reviewing a curated 7 dividend fortresses that pairs higher yields with a focus on resilience and sustainability.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com